{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:19:36Z","timestamp":1782901176869,"version":"3.54.5"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kidney Research UK Training Fellowship","award":["TF2\/2014"],"award-info":[{"award-number":["TF2\/2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40265-016-0575-2","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T06:08:49Z","timestamp":1462255729000},"page":"841-852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease"],"prefix":"10.1007","volume":"76","author":[{"given":"S. N.","family":"Salam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Wilkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"issue":"6","key":"575_CR1","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948\u201355.","journal-title":"Nephrol Dial Transplant."},{"key":"575_CR2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bone.2014.01.016","volume":"61","author":"E Streja","year":"2014","unstructured":"Streja E, Wang HY, Lau WL, Molnar MZ, Kovesdy CP, Kalantar-Zadeh K, et al. Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone. 2014;61:201\u20137.","journal-title":"Bone."},{"issue":"4","key":"575_CR3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607\u201317.","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"575_CR4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208\u201318.","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"575_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519\u201330.","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"575_CR6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","volume":"67","author":"EW Young","year":"2005","unstructured":"Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179\u201387.","journal-title":"Kidney Int."},{"issue":"2","key":"575_CR7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2215\/CJN.01870408","volume":"4","author":"T Adragao","year":"2009","unstructured":"Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, et al. Low bone volume\u2014a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):450\u20135.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"575_CR8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1447-0594.2009.00528.x","volume":"9","author":"A Aoki","year":"2009","unstructured":"Aoki A, Kojima F, Uchida K, Tanaka Y, Nitta K. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients. Geriatr Gerontol Int. 2009;9(3):246\u201352.","journal-title":"Geriatr Gerontol Int."},{"key":"575_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bone.2014.03.048","volume":"64","author":"D Cejka","year":"2014","unstructured":"Cejka D, Weber M, Diarra D, Reiter T, Kainberger F, Haas M. Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease. Bone. 2014;64:33\u20138.","journal-title":"Bone."},{"issue":"1","key":"575_CR10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00198-013-2435-1","volume":"25","author":"M Maravic","year":"2014","unstructured":"Maravic M, Ostertag A, Torres PU, Cohen-Solal M. Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int. 2014;25(1):159\u201365.","journal-title":"Osteoporos Int."},{"issue":"10","key":"575_CR11","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00198-011-1890-9","volume":"23","author":"AL Negri","year":"2012","unstructured":"Negri AL, Del Valle EE, Zanchetta MB, Nobaru M, Silveira F, Puddu M, et al. Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients. Osteoporos Int. 2012;23(10):2543\u201350.","journal-title":"Osteoporos Int."},{"issue":"8","key":"575_CR12","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","volume":"28","author":"TL Nickolas","year":"2013","unstructured":"Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28(8):1811\u201320.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"issue":"1","key":"575_CR13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ndt\/gfn466","volume":"24","author":"M Rodriguez-Garcia","year":"2009","unstructured":"Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andia JB, et al. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant. 2009;24(1):239\u201346.","journal-title":"Nephrol Dial Transplant."},{"issue":"11","key":"575_CR14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945\u201353.","journal-title":"Kidney Int."},{"issue":"4","key":"575_CR15","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793\u2013800.","journal-title":"Kidney Int."},{"issue":"26","key":"575_CR16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"ET Investigators","year":"2012","unstructured":"Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med."},{"issue":"2","key":"575_CR17","first-page":"24","volume":"5","author":"A Lee","year":"2013","unstructured":"Lee A, Belozeroff V, Song X, Diakun D, Goodman W. Cost of treatment and clinical events for secondary hyperparathyroidism. Am J Pharm Benefits. 2013;5(2):24\u201335.","journal-title":"Am J Pharm Benefits."},{"issue":"7","key":"575_CR18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jbmr.5650110714","volume":"11","author":"Y Almaden","year":"1996","unstructured":"Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res Off J Am Soc Bone Miner Res. 1996;11(7):970\u20136.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"issue":"7","key":"575_CR19","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205\u201315.","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"575_CR20","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370\u20138.","journal-title":"Kidney Int."},{"issue":"10","key":"575_CR21","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120\u20133.","journal-title":"J Biol Chem."},{"issue":"4","key":"575_CR22","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1074\/jbc.M207872200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278(4):2206\u201311.","journal-title":"J Biol Chem."},{"issue":"1","key":"575_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.abb.2011.11.003","volume":"523","author":"G Jones","year":"2012","unstructured":"Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012;523(1):9\u201318.","journal-title":"Arch Biochem Biophys."},{"issue":"3","key":"575_CR24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1525-139X.2006.00161.x","volume":"19","author":"E Lewin","year":"2006","unstructured":"Lewin E, Huan J, Olgaard K. Parathyroid growth and suppression in renal failure. Semin Dial. 2006;19(3):238\u201345.","journal-title":"Semin Dial."},{"issue":"5","key":"575_CR25","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1046\/j.1523-1755.2001.00986.x","volume":"60","author":"S Valimaki","year":"2001","unstructured":"Valimaki S, Farnebo F, Forsberg L, Larsson C, Farnebo LO. Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int. 2001;60(5):1666\u201375.","journal-title":"Kidney Int."},{"issue":"3","key":"575_CR26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ki.2009.464","volume":"77","author":"H Galitzer","year":"2010","unstructured":"Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77(3):211\u20138.","journal-title":"Kidney Int."},{"issue":"3","key":"575_CR27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40620-014-0124-6","volume":"28","author":"H Trivedi","year":"2014","unstructured":"Trivedi H, Szabo A, Zhao S, Cantor T, Raff H. Circadian variation of mineral and bone parameters in end-stage renal disease. J Nephrol. 2014;28(3):351\u20139.","journal-title":"J Nephrol."},{"issue":"11","key":"575_CR28","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1093\/ndt\/gfr614","volume":"26","author":"CM Sturgeon","year":"2011","unstructured":"Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results\u2014a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant. 2011;26(11):3440\u20135.","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"575_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.09580911","volume":"8","author":"G Garrett","year":"2013","unstructured":"Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH\u2014a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013;8(2):299\u2013312.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"575_CR30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","volume":"60","author":"MC Monier-Faugere","year":"2001","unstructured":"Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, et al. Improved assessment of bone turnover by the PTH-(1-84)\/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60(4):1460\u20138.","journal-title":"Kidney Int."},{"issue":"2","key":"575_CR31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/ajkd.2002.34519","volume":"40","author":"G Coen","year":"2002","unstructured":"Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, et al. PTH 1-84 and PTH \u201c7-84\u201d in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40(2):348\u201354.","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"575_CR32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1523-1755.2005.00513.x","volume":"68","author":"G Lehmann","year":"2005","unstructured":"Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1\u201384) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68(3):1206\u201314.","journal-title":"Kidney Int."},{"issue":"5","key":"575_CR33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2009.12.041","volume":"55","author":"J Herberth","year":"2010","unstructured":"Herberth J, Branscum AJ, Mawad H, Cantor T, Monier-Faugere MC, Malluche HH. Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study. Am J Kidney Dis. 2010;55(5):897\u2013906.","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"575_CR34","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00198-012-2245-x","volume":"24","author":"M Inaba","year":"2013","unstructured":"Inaba M, Okuno S, Imanishi Y, Ishimura E, Yamakawa T, Shoji S. Increased active PTH (1\u201384) fraction as a predictor of poor mortality in male hemodialysis patients. Osteoporos Int. 2013;24(11):2863\u201370.","journal-title":"Osteoporos Int."},{"issue":"4","key":"575_CR35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5414\/CNP75309","volume":"75","author":"E Zitt","year":"2011","unstructured":"Zitt E, Kirsch AH, Haueis M, Strasak A, Neyer U, Mayer G, et al. The PTH (1\u201384)\/non-PTH (1\u201384) ratio is a risk factor for cardiovascular events in hemodialysis patients. Clin Nephrol. 2011;75(4):309\u201318.","journal-title":"Clin Nephrol."},{"issue":"5","key":"575_CR36","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/ndt\/gfm849","volume":"23","author":"ML Melamed","year":"2008","unstructured":"Melamed ML, Eustace JA, Plantinga LC, Jaar BG, Fink NE, Parekh RS, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant. 2008;23(5):1650\u20138.","journal-title":"Nephrol Dial Transplant."},{"key":"575_CR37","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes CKDMBDWG","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1\u2013130.","journal-title":"Kidney Int Suppl."},{"issue":"6","key":"575_CR38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","volume":"73","author":"FC Barreto","year":"2008","unstructured":"Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, et al. K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73(6):771\u20137.","journal-title":"Kidney Int."},{"issue":"1","key":"575_CR39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000057611","volume":"91","author":"G Coen","year":"2002","unstructured":"Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91(1):103\u201311.","journal-title":"Nephron."},{"issue":"5","key":"575_CR40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/oxfordjournals.ndt.a027404","volume":"11","author":"G Coen","year":"1996","unstructured":"Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant. 1996;11(5):813\u20139.","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"575_CR41","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/ndt\/13.9.2294","volume":"13","author":"G Coen","year":"1998","unstructured":"Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13(9):2294\u2013302.","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"575_CR42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5414\/CNP70296","volume":"70","author":"G Lehmann","year":"2008","unstructured":"Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3\u20135. Clin Nephrol. 2008;70(4):296\u2013305.","journal-title":"Clin Nephrol."},{"issue":"2","key":"575_CR43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5414\/CNP74091","volume":"74","author":"S Beddhu","year":"2010","unstructured":"Beddhu S, Baird B, Ma X, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol. 2010;74(2):91\u20136.","journal-title":"Clin Nephrol"},{"issue":"7","key":"575_CR44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3747\/pdi.2013.00110","volume":"34","author":"CM Rhee","year":"2014","unstructured":"Rhee CM, Molnar MZ, Lau WL, Ravel V, Kovesdy CP, Mehrotra R, et al. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. Perit Dial Int. 2014;34(7):732\u201348.","journal-title":"Perit Dial Int."},{"issue":"5","key":"575_CR45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1053\/j.ajkd.2005.08.013","volume":"46","author":"M Noordzij","year":"2005","unstructured":"Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, et al. The kidney disease outcomes quality initiative (K\/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 2005;46(5):925\u201332.","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"575_CR46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","volume":"70","author":"K Kalantar-Zadeh","year":"2006","unstructured":"Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771\u201380.","journal-title":"Kidney Int."},{"issue":"3","key":"575_CR47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1542-4758.2007.00190.x","volume":"11","author":"N Kimata","year":"2007","unstructured":"Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int Int Symp Home Hemodial. 2007;11(3):340\u20138.","journal-title":"Hemodial Int Int Symp Home Hemodial."},{"issue":"2","key":"575_CR48","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","volume":"26","author":"T Isakova","year":"2011","unstructured":"Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26(2):584\u201391.","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"575_CR49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2006;21(8):1187\u201396.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"issue":"6","key":"575_CR50","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","volume":"88","author":"CS Shinaberger","year":"2008","unstructured":"Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511\u20138.","journal-title":"Am J Clin Nutr."},{"issue":"4","key":"575_CR51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","volume":"54","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;54(4):619\u201337.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"575_CR52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P, Treat to Goal Working G. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245\u201352.","journal-title":"Kidney Int."},{"issue":"4","key":"575_CR53","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","volume":"68","author":"GA Block","year":"2005","unstructured":"Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815\u201324.","journal-title":"Kidney Int."},{"issue":"1","key":"575_CR54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","volume":"42","author":"MS Joy","year":"2003","unstructured":"Joy MS, Finn WF, Group LAMS. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42(1):96\u2013107.","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"575_CR55","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/ndt\/13.9.2303","volume":"13","author":"DI Goldberg","year":"1998","unstructured":"Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant. 1998;13(9):2303\u201310.","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"575_CR56","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407\u201315.","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"575_CR57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000100044","volume":"27","author":"D Russo","year":"2007","unstructured":"Russo D, Corrao S, Miranda I, Ruocco C, Manzi S, Elefante R, et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol. 2007;27(2):152\u20138.","journal-title":"Am J Nephrol."},{"key":"575_CR58","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2369-14-226","volume":"14","author":"C Zhang","year":"2013","unstructured":"Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226.","journal-title":"BMC Nephrol."},{"issue":"2","key":"575_CR59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286\u201391.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"575_CR60","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","volume":"72","author":"WN Suki","year":"2007","unstructured":"Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130\u20137.","journal-title":"Kidney Int."},{"issue":"3","key":"575_CR61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","volume":"16","author":"ND Toussaint","year":"2011","unstructured":"Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton). 2011;16(3):290\u20138.","journal-title":"Nephrology (Carlton)."},{"issue":"4","key":"575_CR62","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","volume":"110","author":"DV Barreto","year":"2008","unstructured":"Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification\u2014results from the BRiC study. Nephron Clin Pract. 2008;110(4):c273\u201383.","journal-title":"Nephron Clin Pract."},{"issue":"6","key":"575_CR63","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","volume":"51","author":"W Qunibi","year":"2008","unstructured":"Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51(6):952\u201365.","journal-title":"Am J Kidney Dis."},{"issue":"10","key":"575_CR64","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/ndt\/gfp350","volume":"24","author":"SA Jamal","year":"2009","unstructured":"Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24(10):3168\u201374.","journal-title":"Nephrol Dial Transplant."},{"issue":"9900","key":"575_CR65","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","volume":"382","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268\u201377.","journal-title":"Lancet."},{"key":"575_CR66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2369-12-20","volume":"12","author":"DW Mudge","year":"2011","unstructured":"Mudge DW, Johnson DW, Hawley CM, Campbell SB, Isbel NM, van Eps CL, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol. 2011;12:20.","journal-title":"BMC Nephrol."},{"key":"575_CR67","unstructured":"2012 annual report of the dialysis outcomes and practice patterns study: hemodialysis data 1997\u20132011. Ann Arbor: Arbor Research Collaborative for Health; 2012."},{"issue":"3","key":"575_CR68","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638\u201347.","journal-title":"Kidney Int."},{"issue":"10","key":"575_CR69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.23","volume":"77","author":"GA Block","year":"2010","unstructured":"Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77(10):897\u2013903.","journal-title":"Kidney Int."},{"issue":"1","key":"575_CR70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10157-013-0815-7","volume":"18","author":"M Fukagawa","year":"2014","unstructured":"Fukagawa M, Kasuga H, Joseph D, Sawata H, Junge G, Moore A, et al. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. Clin Exp Nephrol. 2014;18(1):135\u201343.","journal-title":"Clin Exp Nephrol."},{"issue":"8","key":"575_CR71","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1797.2011.01509.x","volume":"16","author":"JB Chen","year":"2011","unstructured":"Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16(8):743\u201350.","journal-title":"Nephrology (Carlton)."},{"issue":"5","key":"575_CR72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000081023","volume":"24","author":"EA Gonzalez","year":"2004","unstructured":"Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503\u201310.","journal-title":"Am J Nephrol."},{"issue":"1","key":"575_CR73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31\u20138.","journal-title":"Kidney Int."},{"issue":"5","key":"575_CR74","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/ki.2014.372","volume":"87","author":"RA Oliveira de","year":"2014","unstructured":"de Oliveira RA, Barreto FC, Mendes M, Dos Reis LM, Castro JH, Britto ZM, et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2014;87(5):1039\u201345.","journal-title":"Kidney Int."},{"issue":"8","key":"575_CR75","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004\u201313.","journal-title":"Kidney Int."},{"issue":"1","key":"575_CR76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ki.2008.501","volume":"75","author":"P Ravani","year":"2009","unstructured":"Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88\u201395.","journal-title":"Kidney Int."},{"issue":"4","key":"575_CR77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115\u201325.","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"575_CR78","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","volume":"70","author":"F Tentori","year":"2006","unstructured":"Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70(10):1858\u201365.","journal-title":"Kidney Int."},{"issue":"9","key":"575_CR79","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","volume":"27","author":"M Cozzolino","year":"2012","unstructured":"Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH \u2264150\u00a0pg\/mL: results of the Italian FARO Survey. Nephrol Dial Transplant. 2012;27(9):3588\u201394.","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"575_CR80","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","volume":"168","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168(4):397\u2013403.","journal-title":"Arch Intern Med."},{"issue":"8","key":"575_CR81","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/ki.2008.343","volume":"74","author":"M Naves-Diaz","year":"2008","unstructured":"Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008;74(8):1070\u20138.","journal-title":"Kidney Int."},{"issue":"8","key":"575_CR82","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","volume":"19","author":"AB Shoben","year":"2008","unstructured":"Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19(8):1613\u20139.","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"575_CR83","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","volume":"147","author":"SC Palmer","year":"2007","unstructured":"Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147(12):840\u201353.","journal-title":"Ann Intern Med."},{"issue":"9","key":"575_CR84","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/pds.2183","volume":"20","author":"RD Kilpatrick","year":"2011","unstructured":"Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. Pharmacoepidemiol Drug Saf. 2011;20(9):914\u201321.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"575_CR85","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1093\/ndt\/gfn339","volume":"23","author":"G Jean","year":"2008","unstructured":"Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008;23(11):3670\u20136.","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"575_CR86","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/ndt\/gfp370","volume":"24","author":"G Jean","year":"2009","unstructured":"Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009;24(12):3799\u2013805.","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"575_CR87","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2215\/CJN.12761211","volume":"7","author":"LA Armas","year":"2012","unstructured":"Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R. 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol. 2012;7(9):1428\u201334.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"575_CR88","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jcem-72-1-157","volume":"72","author":"AS Dusso","year":"1991","unstructured":"Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab. 1991;72(1):157\u201364.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"575_CR89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1677\/jme.0.0250141","volume":"25","author":"M Hewison","year":"2000","unstructured":"Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol. 2000;25(2):141\u20138.","journal-title":"J Mol Endocrinol."},{"issue":"7","key":"575_CR90","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ndt\/gft001","volume":"28","author":"P Delanaye","year":"2013","unstructured":"Delanaye P, Weekers L, Warling X, Moonen M, Smelten N, Medart L, et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant. 2013;28(7):1779\u201386.","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"575_CR91","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2215\/CJN.06910714","volume":"10","author":"I Bhan","year":"2015","unstructured":"Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, et al. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol. 2015;10(4):611\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"575_CR92","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ajkd.2008.09.020","volume":"53","author":"L Kooienga","year":"2009","unstructured":"Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis. 2009;53(3):408\u201316.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"575_CR93","first-page":"10","volume":"14","author":"P Chandra","year":"2008","unstructured":"Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2008;14(1):10\u20137.","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol."},{"issue":"3","key":"575_CR94","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3945\/ajcn.112.040642","volume":"96","author":"JA Alvarez","year":"2012","unstructured":"Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96(3):672\u20139.","journal-title":"Am J Clin Nutr."},{"issue":"1","key":"575_CR95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","volume":"27","author":"AL Zisman","year":"2007","unstructured":"Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36\u201343.","journal-title":"Am J Nephrol."},{"issue":"1","key":"575_CR96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","volume":"50","author":"Z Al-Aly","year":"2007","unstructured":"Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50(1):59\u201368.","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"575_CR97","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","volume":"321","author":"DL Andress","year":"1989","unstructured":"Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989;321(5):274\u20139.","journal-title":"N Engl J Med."},{"issue":"6976","key":"575_CR98","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"NA Hamdy","year":"1995","unstructured":"Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358\u201363.","journal-title":"BMJ."},{"issue":"4","key":"575_CR99","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfg595","volume":"19","author":"M Rix","year":"2004","unstructured":"Rix M, Eskildsen P, Olgaard K. Effect of 18\u00a0months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19(4):870\u20136.","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"575_CR100","doi-asserted-by":"crossref","first-page":"c268","DOI":"10.1159\/000276579","volume":"114","author":"H Reichel","year":"2010","unstructured":"Reichel H. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. Nephron Clin Pract. 2010;114(4):c268\u201376.","journal-title":"Nephron Clin Pract."},{"key":"575_CR101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2369-15-27","volume":"15","author":"M Lessard","year":"2014","unstructured":"Lessard M, Ouimet D, Leblanc M, Nadeau-Fredette AC, Bell R, Lafrance JP, et al. Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients. BMC Nephrol. 2014;15:27.","journal-title":"BMC Nephrol."},{"issue":"1","key":"575_CR102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1744-9987.2012.01131.x","volume":"17","author":"A Alghareeb","year":"2013","unstructured":"Alghareeb A, Sabry A, Bawadekji H, Alsaran K. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients. Ther Apheresis Dial Off Peer Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Therapy. 2013;17(1):30\u20134.","journal-title":"Ther Apheresis Dial Off Peer Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Therapy."},{"issue":"6","key":"575_CR103","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5414\/CNP65415","volume":"65","author":"F Tarrass","year":"2006","unstructured":"Tarrass F, Yazidi A, Sif H, Zamd M, Benghanem MG, Ramdani B. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease. Clin Nephrol. 2006;65(6):415\u20138.","journal-title":"Clin Nephrol."},{"issue":"5","key":"575_CR104","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","volume":"43","author":"JW Coburn","year":"2004","unstructured":"Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43(5):877\u201390.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"575_CR105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","volume":"51","author":"AU Tan Jr","year":"1997","unstructured":"Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997;51(1):317\u201323.","journal-title":"Kidney Int."},{"issue":"3","key":"575_CR106","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","volume":"37","author":"HM Maung","year":"2001","unstructured":"Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001;37(3):532\u201343.","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"575_CR107","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","volume":"36","author":"JM Frazao","year":"2000","unstructured":"Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000;36(3):550\u201361.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"575_CR108","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47(2):263\u201376.","journal-title":"Am J Kidney Dis."},{"issue":"21","key":"575_CR109","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2012.4176","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Tamez H, Solomon SD. Vitamin D therapy and cardiac function in chronic kidney disease-reply. JAMA J Am Med Assoc. 2012;307(21):2253.","journal-title":"JAMA J Am Med Assoc."},{"issue":"1","key":"575_CR110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000109398","volume":"28","author":"EA Ross","year":"2008","unstructured":"Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008;28(1):97\u2013106.","journal-title":"Am J Nephrol."},{"issue":"3","key":"575_CR111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nep.12029","volume":"18","author":"LM Ong","year":"2013","unstructured":"Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, et al. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton). 2013;18(3):194\u2013200.","journal-title":"Nephrology (Carlton)."},{"issue":"4","key":"575_CR112","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483\u201390.","journal-title":"Kidney Int."},{"issue":"5","key":"575_CR113","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446\u201356.","journal-title":"N Engl J Med."},{"issue":"8","key":"575_CR114","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ki.2011.226","volume":"80","author":"D Hansen","year":"2011","unstructured":"Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int. 2011;80(8):841\u201350.","journal-title":"Kidney Int."},{"issue":"8","key":"575_CR115","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(8):3270\u20138.","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"575_CR116","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfu011","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant. 2014;29(4):899\u2013905.","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"575_CR117","first-page":"1428","volume":"22","author":"R Garside","year":"2007","unstructured":"Garside R, Pitt M, Anderson R, Mealing S, D\u2019Souza R, Stein K. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc. 2007;22(5):1428\u201336.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc."},{"key":"575_CR118","volume-title":"Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy [TA117]","author":"NICE","year":"2007","unstructured":"NICE. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy [TA117]. London: National Institute for Health and Care Excellence; 2007."},{"issue":"15","key":"575_CR119","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325.","journal-title":"N Engl J Med."},{"issue":"4","key":"575_CR120","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/nu5041336","volume":"5","author":"YT Lee","year":"2013","unstructured":"Lee YT, Ng HY, Kuo CC, Chen TC, Wu CS, Chiu TT, et al. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients. Nutrients. 2013;5(4):1336\u201348.","journal-title":"Nutrients."},{"issue":"9","key":"575_CR121","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2215\/CJN.13081211","volume":"7","author":"M Fukagawa","year":"2012","unstructured":"Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T, et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol. 2012;7(9):1473\u201380.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"575_CR122","doi-asserted-by":"crossref","first-page":"c41","DOI":"10.1159\/000212102","volume":"112","author":"M Wilkie","year":"2009","unstructured":"Wilkie M, Pontoriero G, Macario F, Yaqoob M, Bouman K, Braun J, et al. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephron Clin Pract. 2009;112(1):c41\u201350.","journal-title":"Nephron Clin Pract."},{"issue":"4","key":"575_CR123","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327\u201339.","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"575_CR124","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","volume":"10","author":"PS Parfrey","year":"2015","unstructured":"Parfrey PS, Drueke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10(5):791\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"575_CR125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","volume":"85","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191\u20137.","journal-title":"Kidney Int."},{"issue":"5","key":"575_CR126","doi-asserted-by":"crossref","first-page":"755","DOI":"10.5301\/jn.5000056","volume":"25","author":"N Iwamoto","year":"2012","unstructured":"Iwamoto N, Sato N, Nishida M, Hashimoto T, Kobayashi H, Yamasaki S, et al. Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism. J Nephrol. 2012;25(5):755\u201363.","journal-title":"J Nephrol."},{"issue":"4","key":"575_CR127","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jamcollsurg.2011.12.046","volume":"214","author":"J Sharma","year":"2012","unstructured":"Sharma J, Raggi P, Kutner N, Bailey J, Zhang R, Huang Y, et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg. 2012;214(4):400\u20137 (discussion 7\u20138).","journal-title":"J Am Coll Surg."},{"issue":"2","key":"575_CR128","doi-asserted-by":"crossref","first-page":"c113","DOI":"10.1159\/000326683","volume":"119","author":"J Fotheringham","year":"2011","unstructured":"Fotheringham J, Balasubramanian SP, Harrison B, Wilkie M. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival\u2014a single-centre study in a stage 5 chronic kidney disease population. Nephron Clin Pract. 2011;119(2):c113\u201320.","journal-title":"Nephron Clin Pract."},{"issue":"3","key":"575_CR129","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1523-1755.2003.00835.x","volume":"63","author":"FR Santos","year":"2003","unstructured":"Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL. IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 2003;63(3):899\u2013907.","journal-title":"Kidney Int."},{"issue":"7","key":"575_CR130","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943\u201351.","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"575_CR131","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/archsurg.136.9.1064","volume":"136","author":"FF Chou","year":"2001","unstructured":"Chou FF, Chen JB, Lee CH, Chen SH, Sheen-Chen SM. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg. 2001;136(9):1064\u20138.","journal-title":"Arch Surg."},{"issue":"5","key":"575_CR132","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5414\/CN107661","volume":"79","author":"M Yamanouchi","year":"2013","unstructured":"Yamanouchi M, Ubara Y, Hayami N, Suwabe T, Hiramatsu R, Sumida K, et al. Bone mineral density 5\u00a0years after parathyroidectomy in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2013;79(5):380\u20136.","journal-title":"Clin Nephrol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0575-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0575-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0575-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T10:28:20Z","timestamp":1600511300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0575-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":132,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0575-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}